Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10485607 | 1.00 | ACHE (0.59) | ACHECHRM3CHRM2DRD2DRD4 | |
| SCHEMBL250673 | 0.91 | ACHE (0.69) | ACHECHRM3DRD2DRD4DRD3 | |
| SCHEMBL28255691 | 0.85 | DRD2 (0.62) | ACHECHRM3CHRM2DRD2DRD4 | |
| SCHEMBL13016528 | 0.84 | ACHE (0.67) | ACHECHRM3CHRM2DRD2DRD4 | |
| SCHEMBL7380311 | 0.83 | MC4R (0.53) | ACHE | |
| SCHEMBL8712818 | 0.82 | ACHE (0.52) | ACHEMALT1 | |
| SCHEMBL8327851 | 0.80 | ACHE (0.57) | ACHECHRM3CHRM2DRD2 | |
| SCHEMBL7624980 | 0.80 | ACHE (0.57) | ACHE | |
| SCHEMBL7240237 | 0.80 | ACHE (0.69) | ACHECHRM3CHRM2DRD2DRD4 | |
| SCHEMBL8330045 | 0.77 | CASP3 (0.52) | ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123548-A1 | Pth agonists | COWAN DAVID J | 2007-05-31 | — | — | US | disclosed |
| EP-1713782-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077918-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-5607953-A | ANTIISCHEMIC AGENTS | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0344577-B1 | Butenoic or propenoic acid derivatives | EISAI CO LTD (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5382595-A | Antiischemic agents | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0310854-B1 | PROCESS FOR THE MANUFACTURE OF 3-AMINO-1-BENZYL-PYRROLIDINES | BAYER AG (DE) | 1992-05-20 | — | — | EP | disclosed |
| US-5047417-A | Butenoic or propenoic acid derivatives | EISAI CO. LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| US-4910319-A | Process for preparing 3-amino-1-benzylpyrrolidines | BAYER AKTIENGESELLSCHAFT (DE) | 1990-03-20 | — | — | US | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0310854-A1 | Process for the manufacture of 3-amino-1-benzyl-pyrrolidines | BAYER AG (DE) | 1989-04-12 | — | — | EP | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123548-A1 | Pth agonists | PTH1R, SSTR3, CALCR | ACHE 3975/4885CHRM3 35/4885CHRM2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.